STOCK TITAN

Inogen (INGN) Chief Commercial Officer discloses RSU vesting and share disposal

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Inogen Inc's Chief Commercial Officer reports stock transactions linked to vesting restricted stock units. On December 1, 2025, the officer acquired 31,566 shares of common stock at an exercise price of $0 when a portion of a time-based restricted stock award vested. On the same day, 12,943 shares were withheld and disposed of at $6.95 per share to cover tax withholding obligations.

After these transactions, the officer directly owned 37,246 shares of Inogen common stock and held 31,565 restricted stock units. Each restricted stock unit represents the right to receive one share of Inogen common stock, with one-third of the units vesting on each anniversary of the December 1, 2023 vesting commencement date, subject to continued service.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ramade Gregoire

(Last) (First) (Middle)
C/O INOGEN, INC. 859 WARD DRIVE

(Street)
GOLETA CA 93111

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Inogen Inc [ INGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/01/2025 M 31,566 A $0 50,189 D
Common Stock 12/01/2025 F 12,943(1) D $6.95 37,246 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (2) 12/01/2025 M 31,566 (3) (3) Common Stock 31,566 $0 31,565 D
Explanation of Responses:
1. The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2025.
2. Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
3. Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.
/s/ Mary Wright, as Attorney-in-Fact 12/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Inogen (INGN) report on December 1, 2025?

The Chief Commercial Officer of Inogen Inc. (INGN) reported the vesting of 31,566 restricted stock units, which converted into common shares on December 1, 2025. A portion of these shares was then withheld to satisfy tax obligations.

How many Inogen (INGN) shares were sold or withheld for taxes in this Form 4?

The filing states that 12,943 shares of Inogen common stock were disposed of at $6.95 per share to cover the reporting person’s tax withholding liability related to the RSU vesting.

How many Inogen (INGN) shares does the officer own after the reported transactions?

Following the reported transactions, the Chief Commercial Officer directly owned 37,246 shares of Inogen common stock, as disclosed in the Form 4.

What ongoing equity interest does the Inogen (INGN) officer still hold in restricted stock units?

The officer beneficially owned 31,565 restricted stock units after the transaction. Each unit represents a contingent right to receive one share of Inogen common stock.

What is the vesting schedule for the Inogen (INGN) restricted stock units in this filing?

The filing explains that, subject to continued service, one-third of the restricted stock units vest one year from December 1, 2023, and one-third vest on each anniversary of that date in subsequent years.

What is the relationship of the reporting person to Inogen (INGN)?

The reporting person is identified as an officer of Inogen Inc., serving as the company’s Chief Commercial Officer, and is filing individually on this Form 4.

Inogen Inc

NASDAQ:INGN

INGN Rankings

INGN Latest News

INGN Latest SEC Filings

INGN Stock Data

161.53M
23.85M
12.08%
75.12%
3.3%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
GOLETA